{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.77","upperLimit":"7.06","value":"4.67"},{"groupId":"OG001","lowerLimit":"5.68","upperLimit":"11.96","value":"7.72"},{"groupId":"OG002","lowerLimit":"3.94","upperLimit":"42.71","value":"8.61"},{"comment":"The median, upper and lower limits of 95% confidence interval were not evaluable due to fewer number of participants with events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"OS was defined as the time from the date of first dose of study drug to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG000","title":"Pancreatic Cancer Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.","id":"OG001","title":"Metastatic CRC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG002","title":"sqEC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.","id":"OG003","title":"sqNSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"Safety Analysis Set included all participants who received any amount of study drug. Participants without documentation of death at the time of analysis were censored at the date last known to be alive. As pre-specified in the protocol, this outcome measure evaluated and reported data for participants only in the Tumor-Specific Cohorts.","reportingStatus":"POSTED","timeFrame":"Up to approximately 43 months","title":"Overall Survival (OS) in the Tumor-Specific Cohorts","type":"SECONDARY","unitOfMeasure":"months"}